{"product_id":"vstm-vrio-analysis","title":"Verastem, Inc. (VSTM): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Verastem, Inc. (VSTM) truly built to last? Our VRIO analysis cuts straight to the core, examining the Value, Rarity, Inimitability, and Organization of its key resources to determine its sustainable competitive advantage. The findings, summarized as '\u0026amp;O4\u0026amp;', reveal critical strengths and potential vulnerabilities; dive in below to uncover exactly what sets this business apart - or where it might fall short.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 1. FDA-Approved Commercial Product (AVMAPKI FAKZYNJA CO-PACK)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the first real revenue stream from a major regulatory win, and that’s a huge inflection point for Verastem, Inc. The AVMAPKI FAKZYNJA CO-PACK approval is the cornerstone of their near-term story, moving them from pure R\u0026amp;D to commercial entity. Honestly, the initial sales figures suggest a successful, albeit early, market entry for this targeted therapy.\u003c\/p\u003e\n\n\u003cp\u003eThe core value here is immediate, tangible revenue from a product that addresses a significant unmet need. The company reported net product revenue of \u003cstrong\u003e$11.2 million\u003c\/strong\u003e for the third quarter of 2025, which was their first full quarter of commercial sales following the May 2025 accelerated approval. This number nearly doubled analyst expectations of $5.77 million, which definitely validates the commercial strategy for this niche indication.\u003c\/p\u003e\n\n\u003cp\u003eThe rarity is clear-cut: this is the first and only treatment approved by the FDA specifically for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have already had systemic therapy. That first-mover status is gold in biotech, especially when you consider the price point - a 28-day regimen costs \u003cstrong\u003e$48,500\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eImitability is tough because getting a novel, two-drug combination across the finish line for regulatory approval is a massive hurdle. It’s not just about the science; it’s about navigating the clinical trials, like the RAMP-201 study that supported the approval, and securing that accelerated nod. Plus, the National Comprehensive Cancer Network (NCCN) already gave it a Category 2A recommendation in May 2025, which helps adoption.\u003c\/p\u003e\n\n\u003cp\u003eOrganizationally, Verastem, Inc. appears to have been ready to move. They launched the product and immediately activated the \u003cstrong\u003eVerastem Cares™\u003c\/strong\u003e program to help patients navigate access and reimbursement, which is crucial for a high-cost, specialized drug. They ended Q3 2025 with \u003cstrong\u003e$137.7 million\u003c\/strong\u003e in cash, giving them runway into the second half of 2026 to support the rollout.\u003c\/p\u003e\n\n\u003cp\u003eThe competitive advantage is currently sustained because you have first-in-class status in a defined patient population, backed by early payer coverage exceeding \u003cstrong\u003e80%\u003c\/strong\u003e. What this estimate hides, though, is the pressure from the high operating expenses - total operating expenses were $52.0 million in Q3 2025 - and the need for continued clinical validation in the confirmatory Phase III RAMP-301 trial.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick breakdown mapping the VRIO assessment to key commercial and organizational metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Metric (2025 Data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eNet Product Revenue: \u003cstrong\u003e$11.2 million\u003c\/strong\u003e (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eFirst-Ever FDA Approval for Indication (May 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eNovel Combination Therapy; NCCN Category 2A Status (May 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eVerastem Cares™\u003c\/strong\u003e Active; Cash Runway into H2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eTo be fair, the organizational strength is also reflected in the early commercial adoption metrics:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e133\u003c\/strong\u003e prescribers of the CO-PACK by Q3 2025.\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e60%\u003c\/strong\u003e of prescriptions originated from gynecological oncologists.\u003c\/li\u003e\n\u003cli\u003ePayer coverage for the product surpassed \u003cstrong\u003e80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCost of Sales for the quarter was \u003cstrong\u003e$1.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 2. Exclusive License for VS-7375 (Oral KRAS G12D Inhibitor)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOffers a potential best-in-class asset targeting the difficult-to-treat KRAS G12D mutation, which is the most frequently occurring somatic change in Pancreatic Ductal Adenocarcinoma (PDAC) patients, reported in about \u003cstrong\u003e40%\u003c\/strong\u003e of cases. Currently, there are no therapies approved by the U.S. Food and Drug Administration (FDA) specifically targeting KRAS G12D mutations. Preliminary clinical data from the GenFleet study in China indicated partial responses achieved among multiple patients with both pancreatic and advanced lung cancers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; other companies target KRAS, but a potent, selective oral dual ON\/OFF inhibitor is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; the underlying science is known, but the specific molecule's development success is hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the option to license was exercised early in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e. The U.S. Investigational New Drug (IND) application was cleared in \u003cstrong\u003eApril 2025\u003c\/strong\u003e, and the U.S. Phase 1\/2a trial commenced in \u003cstrong\u003eJune 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; its advantage hinges on positive data readouts planned for the \u003cstrong\u003efirst half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey milestones and initial data points related to the VS-7375 program are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKRAS G12D Prevalence in PDAC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePercentage of PDAC patients harboring the mutation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense Option Exercise Date (VSTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEarly exercise of the exclusive license option from GenFleet Therapeutics.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina IND Approval (GenFleet)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproval for the Phase 1\/2 study in China (GFH375).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Patient Dosed (China Phase 1\/2)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst-in-human dosing in the GenFleet study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. IND Clearance Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFDA clearance for the U.S. clinical program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Phase 1\/2a Trial Start Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst patient dosed in the VS-7375-101 study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Monotherapy Starting Dose\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e400 mg QD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStarting dose for monotherapy dose escalation in the U.S. trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned U.S. Data Readout\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFirst half of 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpected timing for an interim safety and efficacy update.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe U.S. Phase 1\/2a study (VS-7375-101) is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy, building upon data from the China study.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. study will assess VS-7375 as a monotherapy and in combination with cetuximab (Erbitux).\u003c\/li\u003e\n\u003cli\u003eThe monotherapy dose escalation phase is referencing an efficacious dose identified in the Phase 1\/2 study conducted in China.\u003c\/li\u003e\n\u003cli\u003eExpansion cohorts are planned for patients with advanced KRAS G12D mutant solid tumors, including Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC).\u003c\/li\u003e\n\u003cli\u003eThe combination cohort is planned for colorectal cancer, subject to results from the Phase 1 dose escalation of VS-7375 and cetuximab.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 3. Clinical Data Package for Avutometinib\/Defactinib Combination\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue: Provides a foundation of safety and efficacy data (e.g., 83% cORR in a dose level cohort) supporting expansion into first-line pancreatic cancer (RAMP 205).\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe RAMP 205 Phase 1\/2 trial in frontline metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated an Overall Response Rate (ORR) of \u003cstrong\u003e83%\u003c\/strong\u003e ($\\mathbf{10\/12}$) in the dose level 1 cohort as of April 25, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\/Cohort\u003c\/th\u003e\n\u003cth\u003eRegimen Component\u003c\/th\u003e\n\u003cth\u003ePatient Count (N)\u003c\/th\u003e\n\u003cth\u003eOverall Response Rate (ORR)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 205 Dose Level 1 (RP2D)\u003c\/td\u003e\n\u003ctd\u003eAvutometinib + Defactinib + Chemotherapy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e83%\u003c\/strong\u003e ($\\mathbf{10\/12}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 205 Dose Level 1 (Initial ASCO 2024 Data)\u003c\/td\u003e\n\u003ctd\u003eAvutometinib + Defactinib + Chemotherapy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e83%\u003c\/strong\u003e ($\\mathbf{5\/6}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 201 (Ovarian Cancer Context)\u003c\/td\u003e\n\u003ctd\u003eAvutometinib + Defactinib\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e44%\u003c\/strong\u003e confirmed ORR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity: Moderate; mature data on a novel-novel combination targeting the RAS\/MAPK pathway is valuable in oncology R\u0026amp;D.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe combination targets the RAS\/MAPK pathway, which is mutated in over \u003cstrong\u003e90%\u003c\/strong\u003e of pancreatic tumors.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability: Low; generating high-quality, multi-cohort clinical data takes years and significant capital.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eResearch \u0026amp; development expenses for the third quarter of 2025 were \u003cstrong\u003e$29.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High; data is being presented at major meetings like ASCO 2025 and used to guide trial expansion.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe dose level 1 regimen was selected as the Recommended Phase 2 Dose (RP2D).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company plans to enroll up to \u003cstrong\u003e29\u003c\/strong\u003e patients at the RP2D cohort.\u003c\/li\u003e\n\u003cli\u003eData was presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.\u003c\/li\u003e\n\u003cli\u003eAs of April 25, 2025, a total of \u003cstrong\u003e60\u003c\/strong\u003e patients had been treated across five dose regimens in RAMP 205.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained; the data package itself is a sunk cost that competitors cannot easily replicate.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eVerastem Oncology ended the third quarter of 2025 with cash, cash equivalents and investments of \u003cstrong\u003e$137.7 million\u003c\/strong\u003e, with an expected cash runway into the second half of \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 4. RAS\/MAPK Pathway Scientific Expertise\/Focus\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Focuses R\u0026amp;D and clinical efforts on a specific, high-need oncogenic pathway, creating deep institutional knowledge and focus.\u003c\/p\u003e\n\u003cp\u003eThe company is committed to advancing new medicines for patients with \u003cstrong\u003eRAS\/MAPK pathway\u003c\/strong\u003e-driven cancers, with pipeline focus including RAF\/MEK inhibition (avutometinib\/defactinib for LGSOC) and KRAS G12D inhibition (VS-7375).\u003c\/p\u003e\n\u003cp\u003eThe expertise is demonstrated through clinical results:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Indication\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 (PDAC, China Data as of May 16, 2025)\u003c\/td\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEfficacy-evaluable patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 (NSCLC, China Data as of May 16, 2025)\u003c\/td\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEfficacy-evaluable patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 (PDAC, China Data as of Sept 27, 2025)\u003c\/td\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40.7%\u003c\/strong\u003e (24\/59)\u003c\/td\u003e\n\u003ctd\u003eHeavily pre-treated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 (PDAC, China Data as of Sept 27, 2025)\u003c\/td\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e96.7%\u003c\/strong\u003e (57\/59)\u003c\/td\u003e\n\u003ctd\u003eHeavily pre-treated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvutometinib + Defactinib (Recurrent LGSOC, RAMP 201 Part A)\u003c\/td\u003e\n\u003ctd\u003eConfirmed Objective Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e45%\u003c\/strong\u003e (13\/29)\u003c\/td\u003e\n\u003ctd\u003eBy BICR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eVS-7375, a dual \u003cstrong\u003eKRAS G12D (ON\/OFF) inhibitor\u003c\/strong\u003e, was found to be more efficacious than KRAS G12D and pan-RAS ON-only inhibitors in preclinical models.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs focus on pathways, but sustained, deep focus on RAS\/MAPK across multiple modalities is less common.\u003c\/p\u003e\n\u003cp\u003eThe focus spans multiple modalities within the pathway, including the RAF\/MEK clamp mechanism of avutometinib and the dual ON\/OFF inhibition of VS-7375.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; expertise can be hired, but deep, integrated knowledge takes time to build.\u003c\/p\u003e\n\u003cp\u003eInvestment in this expertise is reflected in R\u0026amp;D expenditures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch \u0026amp; development expenses for the three months ended September 30, 2024, were \u003cstrong\u003e$24.8 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e78.4%\u003c\/strong\u003e compared to \u003cstrong\u003e$13.9 million\u003c\/strong\u003e for the same period in 2023.\u003c\/li\u003e\n\u003cli\u003eThe increase in Q3 2024 R\u0026amp;D expenses was partly related to a clinical milestone expense reached in the \u003cstrong\u003eGenFleet G12D program\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire corporate strategy, from LGSOC to VS-7375, is built around this pathway.\u003c\/p\u003e\n\u003cp\u003eThe company’s strategic priorities for 2025 centered on the RAS\/MAPK portfolio, including the U.S. launch of avutometinib plus defactinib for recurrent LGSOC and advancing VS-7375.\u003c\/p\u003e\n\u003cp\u003eKey organizational milestones demonstrating commitment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVerastem exercised its option early to license \u003cstrong\u003eVS-7375\u003c\/strong\u003e from GenFleet Therapeutics in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe U.S. Investigational New Drug (IND) application for VS-7375 was cleared in \u003cstrong\u003eApril 2025\u003c\/strong\u003e, leading to a Phase 1\/2a trial initiation in \u003cstrong\u003eJune 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash position as of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, was \u003cstrong\u003e$113.2 million\u003c\/strong\u003e, providing an expected cash runway through the potential approval of avutometinib and defactinib for recurrent LGSOC in mid-\u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it helps focus resources but isn't a moat on its own.\u003c\/p\u003e\n\u003cp\u003eThe focus allows for concentrated resource allocation, evidenced by R\u0026amp;D expenses reaching \u003cstrong\u003e$81.3 million\u003c\/strong\u003e for the full year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e. Early clinical data for VS-7375 in the U.S. cohort cleared the \u003cstrong\u003e400 mg QD\u003c\/strong\u003e and \u003cstrong\u003e600 mg QD\u003c\/strong\u003e monotherapy doses with no dose-limiting toxicities observed.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 5. Strategic Partnership with GenFleet Therapeutics\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides access to the VS-7375 asset and leverages GenFleet’s ongoing Phase 1\/2 study in China, sharing development risk and providing early data. Verastem exercised its exclusive option for VS-7375 in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe value is supported by the encouraging efficacy data from the GenFleet-led Phase 1\/2 monotherapy study in China (GFH375) for advanced KRAS G12D mutant Pancreatic Ductal Adenocarcinoma (PDAC), with a data cutoff of \u003cstrong\u003eSeptember 27, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003ePatient Cohort Size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40.7%\u003c\/strong\u003e (24\/59)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e59\u003c\/strong\u003e efficacy-evaluable patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e96.7%\u003c\/strong\u003e (57\/59)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e59\u003c\/strong\u003e efficacy-evaluable patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Survival (OS) at Month Four\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e92.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEvaluated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Lesion Reduction\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e91.5%\u003c\/strong\u003e of patients\u003c\/td\u003e\n\u003ctd\u003eEvaluated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Recommended Phase 2 Dose (RP2D) identified in the China study was \u003cstrong\u003e600 mg QD\u003c\/strong\u003e. The U.S. Phase 1\/2a trial (VS-7375-101), initiated in \u003cstrong\u003eJune 2025\u003c\/strong\u003e, used a starting dose of \u003cstrong\u003e400 mg\u003c\/strong\u003e based on the GenFleet data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; co-development deals are standard in the industry. The collaboration structure includes an exclusive option to license compounds after Phase 1 milestones.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific terms and the molecule (VS-7375, a dual ON\/OFF inhibitor) are unique to this agreement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the early exercise of the license option for VS-7375 in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e shows effective management of the collaboration terms and commitment to the asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe collaboration agreement was entered into in \u003cstrong\u003eAugust 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGenFleet's IND for VS-7375 (GFH375) was approved in China in \u003cstrong\u003eJune 2024\u003c\/strong\u003e, with the first patient dosed in \u003cstrong\u003eJuly 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVerastem's U.S. IND was cleared in \u003cstrong\u003eApril 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is tied to the success of the licensed asset, VS-7375, in ongoing and future clinical trials, particularly given the lack of FDA-approved KRAS G12D treatments.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 6. Commercialization Infrastructure via IQVIA Collaboration\n\u003c\/h2\u003e\n\n\u003cp\u003eThe strategic collaboration with IQVIA was announced on \u003cstrong\u003eJanuary 13, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLeverages IQVIA's infrastructure to execute the U.S. commercial launch for AVMAPKI FAKZYNJA CO-PACK.\u003c\/li\u003e\n\u003cli\u003eFDA approval for AVMAPKI FAKZYNJA CO-PACK was granted on \u003cstrong\u003eMay 8, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe U.S. launch was initiated within one week of FDA Approval.\u003c\/li\u003e\n\u003cli\u003eNet product revenue reached \u003cstrong\u003e$2.1 million\u003c\/strong\u003e in the first six weeks post-launch.\u003c\/li\u003e\n\u003cli\u003eNet revenue for the third quarter of 2025 was over \u003cstrong\u003e$11 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOutsourcing commercial infrastructure is a common strategy for smaller biotechs.\u003c\/li\u003e\n\u003cli\u003eThe collaboration was announced concurrently with a debt refinancing and equity investment providing a pro forma cash position of \u003cstrong\u003e$128.6 million\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe specific contract terms are proprietary.\u003c\/li\u003e\n\u003cli\u003eThe partnership is intended to accelerate key launch capabilities resulting in \u003cstrong\u003esignificant savings\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe partnership was announced in anticipation of the potential U.S. launch planned for mid-2025; the PDUFA action date was set for \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q2 2025 rose to \u003cstrong\u003e$45.9 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$28.3 million\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eVerastem ended Q2 2025 with cash, cash equivalents, and investments of \u003cstrong\u003e$164.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTemporary; it’s an operational efficiency, not a long-term market barrier.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Date\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA Collaboration Announcement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 13, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStrategic Commercialization Partnership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA Action Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNDA Submission for AVMAPKI FAKZYNJA CO-PACK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMay 8, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproval for AVMAPKI FAKZYNJA CO-PACK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch Timeframe Post-Approval\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOne week\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitiation of U.S. Commercial Execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Product Revenue (First 6 Weeks)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-Launch Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (End of Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$164.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Strength\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to \u003cstrong\u003e$28.3 million\u003c\/strong\u003e in Q2 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 7. Cash Position and Financial Runway into H2 2026\n\u003c\/h2\u003e\n\u003cp\u003e\nThe cash position supports funding for the commercial launch of AVMAPKI FAKZYNJA CO-PACK, ongoing clinical trials, and operations.\n\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\nProvides the necessary capital to fund the commercial launch, ongoing clinical trials (like VS-7375 Phase 1\/2a), and operations without immediate dilution pressure. Ended Q3 2025 with $137.7 million in cash, cash equivalents, and investments.\n\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\nModerate; many development-stage firms struggle with runway; having cash projected past the next 12 months is a strength.\n\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\nLow; this is a result of specific financing actions, such as the April 2025 private placement raising gross proceeds of approximately $75 million.\n\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\nHigh; management secured financing to extend runway into the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\nSustained; sufficient cash flow is critical for surviving the long drug development cycle.\n\u003c\/p\u003e\n\u003cp\u003e\nKey financial and operational metrics supporting the runway assessment:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Period\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$137.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApril 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eH2 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eWith existing cash, product revenue, and warrant exercise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 U.S. Trial Initiation\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVS-7375 Data Update Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1H 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInterim safety and efficacy update\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe company's operational spending in Q3 2025 included:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Expense: \u003cstrong\u003e$29.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A Expense: \u003cstrong\u003e$21.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe VS-7375 Phase 1\/2a trial, initiated in June 2025, has an expected interim safety and efficacy update in \u003cstrong\u003e1H 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 8. Fast Track Designation for VS-7375 in Pancreatic Cancer\n\u003c\/h2\u003e\n\u003cp\u003e\nVS-7375 received FDA Fast Track Designation on July 24, 2025.\n\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\nPotential for more frequent FDA communication and eligibility for rolling review, accelerating regulatory timeline for a key indication in locally advanced or metastatic PDAC with KRAS G12D mutations. The KRAS G12D mutation occurs in approximately 37% of pancreatic cancers. Currently, no FDA-approved therapies specifically target KRAS G12D mutations.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Metric\u003c\/td\u003e\n\u003ctd\u003eNumber of Patients (n)\u003c\/td\u003e\n\u003ctd\u003eResult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Response Rate (ORR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e52%\u003c\/strong\u003e (90% CI, 34%-70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100%\u003c\/strong\u003e (90% CI, 88%-100%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with Tumor Reduction\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e59\u003c\/strong\u003e (Heavily pre-treated cohort)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e91.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Time to Response\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6.2\u003c\/strong\u003e weeks (range, 6.0-24.7)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\nModerate; designation granted selectively by the FDA for drugs addressing serious unmet needs.\n\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\nLow; regulatory designation granted based on preclinical data, not an internal capability.\n\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\nHigh; company successfully navigated the regulatory process to secure this status. Verastem's market capitalization was reported at $294 million at the time of the announcement.\n\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\nTemporary; advantage lasts only until the regulatory review process is complete.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nTreatment-related adverse effects (TRAEs) of grade 3 or 4 severity occurred in 29% of all 62 evaluable patients (irrespective of tumor type).\n\u003c\/li\u003e\n\u003cli\u003e\nTRAEs led to dose reductions in 5%, treatment interruptions in 11%, and treatment discontinuation in 3% of patients.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVerastem, Inc. (VSTM) - VRIO Analysis: 9. Ongoing Global Clinical Trial Execution Capability\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Demonstrates the ability to manage complex, multi-national trials, including the U.S. VS-7375 trial, the China study with GenFleet, and the Japan RAMP 201J study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; managing simultaneous global trials, especially in different regulatory zones, requires specialized operational skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; this is built through experience and established relationships with Contract Research Organizations (CROs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; they are on track to complete enrollment for the Phase 3 RAMP 301 trial by the end of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; operational excellence in clinical execution is a core, hard-to-replicate organizational skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Execution Metrics and Status\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRAMP 301 planned enrollment of 270 patients was completed a full quarter early, with an additional 29 patients added based on IDMC recommendation.\u003c\/li\u003e\n\u003cli\u003eThe estimated primary completion date for RAMP 301 is 2028.\u003c\/li\u003e\n\u003cli\u003eThe U.S. VS-7375 Phase 1\/2a trial is expected to initiate in mid-2025.\u003c\/li\u003e\n\u003cli\u003eThe China VS-7375 Phase 1\/2 study began dosing in July 2024.\u003c\/li\u003e\n\u003cli\u003ePreliminary safety and efficacy data from the Japan RAMP 201J trial had a data extract date of April 11, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eQ3 2025 Financial Breakdown and Q4 2025 Projection\u003c\/strong\u003e:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Actual Amount\u003c\/td\u003e\n\u003ctd\u003eQ4 2025 Projection Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on Q3 Run-Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAssumed Consistent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, General \u0026amp; Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAssumed Consistent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2025 Cash Burn Projection\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$52.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProjection based on Q3 Expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Q4 2025 cash burn projection, based on the Q3 operating expenses of \u003cstrong\u003e$52.0 million\u003c\/strong\u003e, is projected to be \u003cstrong\u003e$52.0 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516279185557,"sku":"vstm-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vstm-vrio-analysis.png?v=1740228571","url":"https:\/\/dcf-model.com\/es\/products\/vstm-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}